When these cell lines were grafted into mice and treated with CPE intraperitoneal injections, the growth of tumors were inhibited and the survival time of mice was prolonged, suggesting that CLDN3 and CLDN4 may be potential new targets for the treatment of refractory ovarian cancer with great application prospects. The gene discussed is CLDN4; the disease is ovarian cancer.